GT199800204A - Composicion farmaceutica bebible. - Google Patents

Composicion farmaceutica bebible.

Info

Publication number
GT199800204A
GT199800204A GT199800204A GT199800204A GT199800204A GT 199800204 A GT199800204 A GT 199800204A GT 199800204 A GT199800204 A GT 199800204A GT 199800204 A GT199800204 A GT 199800204A GT 199800204 A GT199800204 A GT 199800204A
Authority
GT
Guatemala
Prior art keywords
pharmaceutical composition
amount
betacd
chlorhydrate
equal
Prior art date
Application number
GT199800204A
Other languages
English (en)
Inventor
Claude Aleman
Philippe Bastard
Marielle Bonnel
Thierry Breul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199800204A publication Critical patent/GT199800204A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)

Abstract

SOLUCION ACUOSA A BASE DE CLORHIDRATO DE 1[2(2NAFTIL)ETIL]4(3TRIFLUOROMETILFENIL)1,2,3,6TETRAHIDROPIRIDINA (CLORHIDRATO DE SR 57746 ) CARACTERIZADA PORQUE COMPRENDE: A) UNA CANTIDAD NO NULA DE betaCD INFERIOR O IGUAL A 50 MG/ML; B) UNA CANTIDAD NO NULA DE CLORHIDRATO DE SR 57746 (EN MG/ML) INFERIOR O IGUAL AL DECIMO DE LA CANTIDAD DE betaCD EXPRESADA EN MG/ML; C) UN ACIDO O UN TAMPON FARMACEUTICAMENTE ACEPTABLE PARA ASEGURAR UN PH INFERIOR O IGUAL A 3; ENTENDIENDOSE QUE PARA UNA CANTIDAD DE betaCD QUE VA DE 30 A 50 MG/ML, LA CANTIDAD DE CLORHIDRATO DE SR 57746, VERIFICA LA ECUACION (I), QUE SE MUESTRA EN EL EXPEDIENTE.
GT199800204A 1997-12-24 1998-12-22 Composicion farmaceutica bebible. GT199800204A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9716529A FR2772614B1 (fr) 1997-12-24 1997-12-24 Solution aqueuse a base de chlorhydrate de 1- [ 2-(2-naphtyl)ethyl]-4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine et composition pharmaceutique buvable en contenant

Publications (1)

Publication Number Publication Date
GT199800204A true GT199800204A (es) 2000-06-14

Family

ID=9515152

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199800204A GT199800204A (es) 1997-12-24 1998-12-22 Composicion farmaceutica bebible.

Country Status (25)

Country Link
US (1) US6191137B1 (es)
EP (1) EP1041984B1 (es)
JP (1) JP2002510599A (es)
AR (1) AR017722A1 (es)
AT (1) ATE252384T1 (es)
AU (1) AU1880599A (es)
BR (1) BR9814414A (es)
CA (1) CA2315696C (es)
CO (1) CO4970813A1 (es)
DE (1) DE69819203T2 (es)
DK (1) DK1041984T3 (es)
DZ (1) DZ2676A1 (es)
ES (1) ES2209238T3 (es)
FR (1) FR2772614B1 (es)
GT (1) GT199800204A (es)
HU (1) HUP0101012A3 (es)
MY (1) MY117156A (es)
NO (1) NO20003284L (es)
PT (1) PT1041984E (es)
SA (2) SA99191003B1 (es)
SI (1) SI1041984T1 (es)
TW (1) TW536409B (es)
UY (1) UY25320A1 (es)
WO (1) WO1999033466A1 (es)
ZA (1) ZA9811824B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053883A1 (en) * 2003-03-25 2007-03-08 The Johns Hopkins University Neuronal cell lineages and methods of production thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.

Also Published As

Publication number Publication date
DE69819203D1 (de) 2003-11-27
TW536409B (en) 2003-06-11
NO20003284D0 (no) 2000-06-22
AU1880599A (en) 1999-07-19
CO4970813A1 (es) 2000-11-07
ZA9811824B (en) 1999-06-29
CA2315696A1 (en) 1999-07-08
ES2209238T3 (es) 2004-06-16
HUP0101012A3 (en) 2002-12-28
DK1041984T3 (da) 2004-02-16
DZ2676A1 (fr) 2004-09-19
MY117156A (en) 2004-05-31
DE69819203T2 (de) 2004-07-15
SI1041984T1 (en) 2004-04-30
FR2772614B1 (fr) 2000-03-10
EP1041984A1 (fr) 2000-10-11
FR2772614A1 (fr) 1999-06-25
US6191137B1 (en) 2001-02-20
BR9814414A (pt) 2000-10-10
SA99191002B1 (ar) 2006-03-07
AR017722A1 (es) 2001-09-12
HUP0101012A2 (hu) 2001-08-28
PT1041984E (pt) 2004-02-27
EP1041984B1 (fr) 2003-10-22
WO1999033466A1 (fr) 1999-07-08
SA99191003B1 (ar) 2006-10-02
JP2002510599A (ja) 2002-04-09
NO20003284L (no) 2000-08-24
CA2315696C (en) 2008-01-29
UY25320A1 (es) 2000-10-31
ATE252384T1 (de) 2003-11-15

Similar Documents

Publication Publication Date Title
YU23599A (sh) Stabilizovani antihistaminski sirup
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
BR9810658A (pt) Composições farmacêuticas contendo hemissulfato de eletriptano e cafeìna.
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
MY111136A (en) Oral formulations of an antifungal.
PT1311285E (pt) Composicao farmaceutica liquida contendo um derivado de eritropoietina
BG104544A (en) Novel acylguanadine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
DK0889875T3 (da) Cycloproylalkansyrederivater
NO962841D0 (no) Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler
AR042472A1 (es) Preparaciones de liberacion controlada que comprenden tramadol y topiramato
HK1029060A1 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
IL141236A0 (en) New oral formulations for 5-ht4 agonists or antagonists
PA8451701A1 (es) Formulacion inyectable transparente de compuesto anestesico
ID22763A (id) Komposisi penstabil tibolon
PT1067934E (pt) Solucao anti-depressiva liquida oral
AU1031697A (en) Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions
IL83086A0 (en) Stable,injectable solutions of vinca dimer salts
WO2001030391A3 (en) Pharmaceutical composition containing midazolam
GT199800204A (es) Composicion farmaceutica bebible.
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
BG103306A (en) Liquid allendronate compositions
ES2197781A1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
NZ507407A (en) Stable mitoxantrone solutions
EP1027051A4 (en) ANTITHROMBOTIC AGENTS